TY - JOUR
T1 - Can the administration of platelet lysates to the brain help treat neurological disorders?
AU - Nebie, Ouada
AU - Buée, Luc
AU - Blum, David
AU - Burnouf, Thierry
N1 - Funding Information:
We thank the Ministry of Science and Technology (MOST) of Taiwan (107-2314-B-038-and 110-2314-B-038-079), the National Health Research Institute of Taiwan (NHRI-EX110-10920EI), Taipei Medical University (TMU) Higher Education Sprout Project MoE (DP2-107-21121-01N 09) and PhD fellowship; Université de Lille, France (CABRI/MOBLILEX grant); Bilateral Orchid research project (MOST and French Association of Taiwan-Campus France; 108-2911-I-038-503); Taipei Medical University, International Collaborative Research Project Funding 108–3805-005-111; International Laboratory funding scheme supported by the University of Lille and TMU (NeuroTMULille); Inserm, CNRS, Université de Lille and CHU Lille (Programmes d’Investissements d’Avenir LabEx (excellence laboratory), DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer’s disease).
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2022/7
Y1 - 2022/7
N2 - Neurodegenerative disorders of the central nervous system (CNS) and brain traumatic insults are characterized by complex overlapping pathophysiological alterations encompassing neuroinflammation, alterations of synaptic functions, oxidative stress, and progressive neurodegeneration that eventually lead to irreversible motor and cognitive dysfunctions. A single pharmacological approach is unlikely to provide a complementary set of molecular therapeutic actions suitable to resolve these complex pathologies. Recent preclinical data are providing evidence-based scientific rationales to support biotherapies based on administering neurotrophic factors and extracellular vesicles present in the lysates of human platelets collected from healthy donors to the brain. Here, we present the most recent findings on the composition of the platelet proteome that can activate complementary signaling pathways in vivo to trigger neuroprotection, synapse protection, anti-inflammation, antioxidation, and neurorestoration. We also report experimental data where the administration of human platelet lysates (HPL) was safe and resulted in beneficial neuroprotective effects in established rodent models of neurodegenerative diseases such as Parkinson’s disease, Alzheimer's disease, traumatic brain injury, and stroke. Platelet-based biotherapies, prepared from collected platelet concentrates (PC), are emerging as a novel pragmatic and accessible translational therapeutic strategy for treating neurological diseases. Based on this assumption, we further elaborated on various clinical, manufacturing, and regulatory issues that need to be addressed to ensure the ethical supply, quality, and safety of HPL preparations for treating neurodegenerative and traumatic pathologies of the CNS. HPL made from PC may become a unique approach for scientifically based treatments of neurological disorders readily accessible in low-, middle-, and high-income countries. Graphical abstract: [Figure not available: see fulltext.].
AB - Neurodegenerative disorders of the central nervous system (CNS) and brain traumatic insults are characterized by complex overlapping pathophysiological alterations encompassing neuroinflammation, alterations of synaptic functions, oxidative stress, and progressive neurodegeneration that eventually lead to irreversible motor and cognitive dysfunctions. A single pharmacological approach is unlikely to provide a complementary set of molecular therapeutic actions suitable to resolve these complex pathologies. Recent preclinical data are providing evidence-based scientific rationales to support biotherapies based on administering neurotrophic factors and extracellular vesicles present in the lysates of human platelets collected from healthy donors to the brain. Here, we present the most recent findings on the composition of the platelet proteome that can activate complementary signaling pathways in vivo to trigger neuroprotection, synapse protection, anti-inflammation, antioxidation, and neurorestoration. We also report experimental data where the administration of human platelet lysates (HPL) was safe and resulted in beneficial neuroprotective effects in established rodent models of neurodegenerative diseases such as Parkinson’s disease, Alzheimer's disease, traumatic brain injury, and stroke. Platelet-based biotherapies, prepared from collected platelet concentrates (PC), are emerging as a novel pragmatic and accessible translational therapeutic strategy for treating neurological diseases. Based on this assumption, we further elaborated on various clinical, manufacturing, and regulatory issues that need to be addressed to ensure the ethical supply, quality, and safety of HPL preparations for treating neurodegenerative and traumatic pathologies of the CNS. HPL made from PC may become a unique approach for scientifically based treatments of neurological disorders readily accessible in low-, middle-, and high-income countries. Graphical abstract: [Figure not available: see fulltext.].
KW - Brain
KW - Extracellular vesicles
KW - Growth factors
KW - Neuroprotection
KW - Neurorestoration
KW - Platelet neurotrophins
UR - http://www.scopus.com/inward/record.url?scp=85133004965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133004965&partnerID=8YFLogxK
U2 - 10.1007/s00018-022-04397-w
DO - 10.1007/s00018-022-04397-w
M3 - Review article
C2 - 35750991
AN - SCOPUS:85133004965
SN - 1420-682X
VL - 79
JO - Cellular and Molecular Life Sciences
JF - Cellular and Molecular Life Sciences
IS - 7
M1 - 379
ER -